InvestorsHub Logo
Followers 1
Posts 81
Boards Moderated 0
Alias Born 07/27/2006

Re: fink post# 146

Friday, 08/12/2011 2:11:26 AM

Friday, August 12, 2011 2:11:26 AM

Post# of 196

Nice article. Thanks Yahoo, but could ya name a few names next time. Sounds like us.


Not MITI's antibody method but directly modifying the T-cells themselves. From the article

In this issue of the Journal, Porter and colleagues5 describe a heavily pretreated patient with chronic lymphocytic leukemia (CLL) who had a complete remission associated with the tumor lysis syndrome after adoptive immunotherapy with second-generation anti-CD19 chimeric antigen receptor–modified T cells. Four days after receiving chemotherapy with pentostatin and cyclophosphamide for depletion of lymphocytes, the patient received 1.42×107 transduced T cells over 3 days with no additional cytokines. Unselected peripheral-blood T cells were infected with a self-inactivating lentiviral vector carrying genes for the chimeric antigen receptor. These genes included the single-chain Fv from the hypervariable region of a human CD19-specific murine antibody, a hinge region, and human 4-1BB and CD3-zeta signaling domains.


CD19 is the target of MT103

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.